At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 683 enrolled
Drug / intervention
CD5024 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Randomized, Double Blind, 12 Week Vehicle Controlled, Parallel Group Study Assessing the Efficacy and Safety of CD5024 1 % Cream Versus Vehicle Cream in Subjects With Papulopustular Rosacea, Followed by a 40 Week Investigator Blinded Extension Comparing the Long Term Safety of CD5024 1% Cream Versus Azelaic Acid 15 % Gel.
In Brief
A Phase 3 clinical trial evaluating CD5024 and Azelaic acid 15% Gel for Papulopustular Rosacea (PPR). Completed, enrolled 683 participants across 50 sites in 2 countries.
Detailed Summary
The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be safe up to 12 months.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPapulopustular Rosacea (PPR)
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2011
First PostedDec 2011
Primary CompletionJul 2013
Study CompletionAug 2013
TodayJul 2026
First PostedDec 16, 2011
Enrollment StartDec 1, 2011
Primary CompletionJul 1, 2013
Study CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 14.5 years ago
Interventions
CD5024drug
CD5024 1% Cream, once daily
Azelaic acid 15% Geldrug
Topical Gel applied twice daily